Literature DB >> 3493065

Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.

D J FitzGerald, M J Bjorn, R J Ferris, J L Winkelhake, A E Frankel, T C Hamilton, R F Ozols, M C Willingham, I Pastan.   

Abstract

An immunotoxin composed of an antibody to the human transferrin receptor (454A12) and ricin A chain (RTA) was shown to inhibit the growth of NIH:OVCAR-3 tumors in a nude mouse model of human ovarian cancer. Inhibition of tumor growth by 454A12-RTA was related to the dose administered. The antitumor activity of the immunotoxin was blocked by coinjection of excess antibody with immunotoxin. An immunotoxin made using 454A12 and recombinant ricin A chain (rRTA) had an activity similar to that made with native RTA. The administration of 10 micrograms or greater of the immunotoxin 454A12-RTA/rRTA had significant antitumor activity. The injection of 30 micrograms of an irrelevant immunotoxin, MOPC21-RTA, or 30 to 500 micrograms of the 454A12 antibody had no antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.

Authors:  O Rostaing-Capaillon; P Casellas
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Therapeutic strategies with monoclonal antibodies and immunoconjugates.

Authors:  V S Byers; R W Baldwin
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.

Authors:  D C Blakey; P E Pinder; A F Wright
Journal:  Cell Biophys       Date:  1994

Review 5.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.

Authors:  H J Haisma; E Boven; M van Muijen; R De Vries; H M Pinedo
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Nitric oxide is an important mediator for tumoricidal activity in vivo.

Authors:  R Farias-Eisner; M P Sherman; E Aeberhard; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.

Authors:  M J Bjorn; H S Smith; S H Dairkee
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.

Authors:  P Brusa; F Pietribiasi; G Bussolati; F Dosio; R Arione; P M Comoglio; M Prat; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 10.  The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.

Authors:  J Simpson; J Schlom
Journal:  Yale J Biol Med       Date:  1988 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.